GSK Q2 Profit Climbs; Now Sees FY25 Targets Towards Top End Of Range

GSK reported robust second-quarter performance, with profit before tax climbing 26% and sales increasing 6% at constant exchange rates, primarily driven by strong growth in Specialty Medicines. Reflecting this momentum, the company upgraded its 2025 guidance, now anticipating core earnings per share and turnover to reach the top end of their previously stated ranges, reinforcing confidence in its long-term outlook.

Analysis

GSK plc demonstrated robust financial health in its second-quarter results, highlighted by a 26% year-over-year increase in profit before tax to £1.89 billion and a 23% rise in earnings per share to 35.5 pence. While reported sales saw a marginal 1% increase, the underlying operational strength is more accurately reflected by the 6% sales growth at constant exchange rates (CER). This performance was primarily fueled by the Specialty Medicines division, which achieved double-digit sales growth in its core Respiratory, Immunology & Inflammation, Oncology, and HIV segments. Critically, management has translated this momentum into increased confidence for the full fiscal year 2025, upgrading its guidance for turnover, core operating profit, and core EPS to the top end of their previously stated ranges. This positive outlook is further reinforced by an increased dividend of 16 pence per share, up from 15 pence in the prior year, signaling strong cash flow generation and a commitment to shareholder returns.

Key Decisions for Investors

• The strong earnings beat and upgraded 2025 guidance support a bullish outlook, suggesting investors may view any market weakness as a potential buying opportunity.
• Monitor the performance of the Specialty Medicines division in subsequent quarters, as its continued double-digit growth is the central pillar of the company's current success and positive forecast.
• Factor the increased dividend into total return calculations, as management's confidence in raising shareholder payouts alongside positive guidance reinforces the stock's potential for both income and capital appreciation.